<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="461">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905904</url>
  </required_header>
  <id_info>
    <org_study_id>ulkü_2</org_study_id>
    <nct_id>NCT01905904</nct_id>
  </id_info>
  <brief_title>Sevoflurane in Electroconvulsive Therapy</brief_title>
  <official_title>The Comparision of Different Doses of Sevoflurane for Induction of General Anesthesia in Electroconvulsive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to investigate the effects of different doses of sevoflurane
      used in electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and
      recovery profiles
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean
      arterial pressure (MAP) values, and recovery times were recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>sevoflurane used in electroconvulsive therapy (ECT) on duration of seizure</measure>
    <time_frame>taken prior to the seizure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>sevoflurane used in electroconvulsive therapy (ECT) on hemodynamic response.</measure>
    <time_frame>taken prior to the seizure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>ECT</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>sevorane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevorane 4% concentration during anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevorane %7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevorane 7% concentration during anesthesia induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevorane</intervention_name>
    <description>Sevorane 4% Sevorane 7%</description>
    <arm_group_label>sevorane</arm_group_label>
    <arm_group_label>sevorane %7</arm_group_label>
    <other_name>Sevoflurane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study included 25 patients of American Society of Anesthesiologists (ASA) physical
             status I-II aged between 18-60 years who were scheduled for ECT sessions under
             general anesthesia

        Exclusion Criteria:

          -  Pregnancy

          -  Cerebrovascular disease

          -  Epilepsy

          -  Unstable cardiovascular disease

          -  Chronic obstructive pulmonary disease; and

          -  Renal or hepatic failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huseyin Toprak, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inonu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inonu Unıversity School of Medicine</name>
      <address>
        <city>Malatya</city>
        <zip>44100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 22, 2013</lastchanged_date>
  <firstreceived_date>July 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Ülkü Özgül</investigator_full_name>
    <investigator_title>assistant profesor</investigator_title>
  </responsible_party>
  <keyword>electroconvulsive therapy</keyword>
  <keyword>seizures</keyword>
  <keyword>sevoflurane</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
